Iptacopan
Pre-clinicalActive 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
C3 Glomerulopathy (C3G)
Conditions
C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH)
Trial Timeline
— → —
NCT ID
NCT05222412About Iptacopan
Iptacopan is a pre-clinical stage product being developed by Novartis for C3 Glomerulopathy (C3G). The current trial status is active. This product is registered under clinical trial identifier NCT05222412. Target conditions include C3 Glomerulopathy (C3G), Paroxysmal Nocturnal Hemoglobinuria (PNH).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05222412 | Pre-clinical | Active |
| NCT06994845 | Phase 3 | Recruiting |
| NCT06903234 | Pre-clinical | Active |
| NCT06797518 | Phase 2 | Recruiting |
| NCT06517758 | Phase 3 | Recruiting |
| NCT05935215 | Phase 3 | Recruiting |
| NCT05630001 | Phase 3 | Completed |
| NCT04889430 | Phase 3 | Active |
| NCT05086744 | Phase 2 | Terminated |
| NCT04747613 | Phase 3 | Active |
| NCT03439839 | Phase 2 | Completed |
Competing Products
5 competing products in C3 Glomerulopathy (C3G)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LNP023 | Novartis | Phase 3 | 77 |
| Avacopan + Avacopan Matching Placebo | Amgen | Phase 2 | 51 |
| ARO-C3 + Placebo | Arrowhead Pharmaceuticals | Phase 1/2 | 38 |
| BCX9930 | BioCryst Pharmaceuticals | Phase 2 | 47 |
| OMS906 study drug | Omeros Corporation | Phase 2 | 47 |